Kiniksa Pharmaceuticals/$KNSA

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.

Ticker

$KNSA
Sector
Primary listing

Employees

-

KNSA Metrics

BasicAdvanced
$2.8B
573.78
$0.07
0.05
-

What the Analysts think about KNSA

Analyst ratings (Buy, Hold, Sell) for Kiniksa Pharmaceuticals stock.

Bulls say / Bears say

For Q2 2025, ARCALYST generated $156.8 million in net product revenue, representing 52% year-over-year growth and leading to an increased 2025 sales outlook of $625–$640 million, highlighting strong commercial momentum in recurrent pericarditis. (GlobeNewswire)
Kiniksa has started the dose-finding phase of the Phase 2/3 trial for KPL-387 in recurrent pericarditis, with Phase 2 data expected in the second half of 2026, moving forward with a potentially differentiated monthly subcutaneous therapy. (GlobeNewswire)
As of June 30, 2025, Kiniksa had $307.8 million in cash and equivalents and no debt, providing a strong balance sheet to support its Phase 3 programs and ongoing operations. (GlobeNewswire)
The company discontinued development of abiprubart in Sjögren’s disease and ended its license for mavrilimumab, narrowing its pipeline and incurring about $19–$17 million in expected termination-related expenses. (FierceBiotech)
Total operating expenses increased to $136.6 million in Q2 2025, up from $108.7 million a year earlier, mainly due to higher collaboration costs and share-based compensation, which could pressure future profitability. (GlobeNewswire)
KPL-387’s Phase 2/3 results are not expected until the second half of 2026, so potential market entry is unlikely before 2028/2029, leaving the company heavily reliant on ARCALYST for revenue. (SEC Form 10-K; GlobeNewswire)
Data summarised monthly by Lightyear AI. Last updated on 1 Oct 2025.

KNSA Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

KNSA Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $KNSA

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs